Dicumarol
(Dicumarols)PreclinicalSmall molecule
AbbVieDicumarol is one of 8 small molecule programs targeting Head Injury. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
7
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Head Injury
#DrugCompanyPhaseTrials
1Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Epsom Salt
FFresenius Kabi USA, LLC
Approved
Depakote
TevaPreclinical
Cortrosyn
NovartisPreclinical
Direct Anticoagulant
BayerPreclinical
Metopirone
TTerezinha de Jesus Esteves Barata
Preclinical
Dicumarol
AbbViePreclinical
Antiplatelet Drugs
BayerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
DICUMAROL
NDA NDA005509
Jan 1, 1982
DICUMAROL
NDA NDA005545
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dicumarols. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]